Nazim Arain Shares The New Standard: Anticoagulation in Cirrhosis
Nazim Arain, Consultant Internal Medicine and Gastroenterologist at Almana Group of Hospitals, shared on LinkedIn:
”Anticoagulation in Cirrhosis: The New Standard
Patients with cirrhosis face an increased risk of thrombotic events like AF and VTE.
It’s now accepted that their coagulation is “rebalanced,” making anticoagulation the standard of care to reduce stroke/thrombosis risk!
The primary bleeding risk is linked to portal hypertension, NOT general clotting deficiency.
Direct Oral Anticoagulants (DOACs) can be considered for Child-Pugh A and Bpatients.
LMWH often preferred in Child-Pug-C.
Read the full review.”
Read the full review article here.
Article: Anticoagulation in cirrhosis
Authors: Lara Roberts
Stay updated on all scientific advances with Hemostasis Today.
-
Jan 25, 2026, 15:42Francesco Lo Monaco on Heart Disease Starting Quiet While Your Labs Speak First
-
Jan 25, 2026, 15:33Wilfried Dinh: Why Heart Patients Still Have Events Despite ”Optimal” Cardiovascular Therapy
-
Jan 25, 2026, 15:25Muhammad Ibrahim on Efficacy and Safety of Extended DOACs Use in VTE
-
Jan 25, 2026, 15:08Tushar Pandey on Managing Thrombotic Thrombocytopenic Purpura
-
Jan 25, 2026, 14:55Carolina Contreras Cuevas Shares a Nationwide Study on VTE in PAD
-
Jan 25, 2026, 14:40Jeannie Devereaux Links PRP and Physical Therapy
-
Jan 25, 2026, 14:25Heghine Khachatryan on Anticoagulation After AFib Ablation: New Evidence from NEJM
-
Jan 25, 2026, 12:42Lale Tokgözoğlu on Cardiovascular Risk Factors in Women
-
Jan 25, 2026, 12:32Dino Mehic on Bleeding Assessment Tools and QoL in BDUC